At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 11 enrolled
Drug / intervention
Abemaciclib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/IB Trial of Abemaciclib Alone or in Combination With MK-6482 in Advanced Renal Cell Carcinoma
In Brief
A Phase 1 clinical trial evaluating Abemaciclib and MK-6482 for Clear Cell Renal Cell Carcinoma. Completed, enrolled 11 participants across 1 site.
Detailed Summary
This research study will assess whether abemaciclib alone or in combination with MK-6482 are safe and effective in slowing down the growth of clear cell renal cell carcinoma (ccRCC). The names of the study drugs in this investigational combination are: * Abemaciclib * MK-6482
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsClear Cell Renal Cell Carcinoma
CountriesUnited States
CollaboratorsEli Lilly and Company, National Cancer Institute (NCI)
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedNov 2020
Enrollment StartDec 2020
Primary CompletionFeb 2024
Study CompletionAug 2024
TodayJul 2026
First PostedNov 13, 2020
Enrollment StartDec 31, 2020
Primary CompletionFeb 9, 2024
Study CompletionAug 4, 2024
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 5.6 years ago
Interventions
Abemaciclibdrug
Tablet taken orally
MK-6482drug
Tablet taken orally